
SureNano Science's GEP-44 Targets Next-Generation GLP-1 Market with Triple Agonist Mechanism
SureNano Science Ltd. is advancing GEP-44, a patented triple agonist therapy for obesity and metabolic disorders, aiming to improve upon first-generation GLP-1 drugs with better tolerability and potential non-injectable delivery.
Read full story























